AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...
AbbVie's underlying business remains strong, and so does its dividend program. The company is a Dividend King with 52 ...
Despite the death of its golden goose, AbbVie expects to achieve high single-digit compound annual sales growth to the end of ...
Emraclidine, a potential treatment for schizophrenia, is expected to yield Phase 2 registrational data by the end of 2024. If successful, AbbVie plans to file with the FDA in 2025 for a potential ...
Shares in AbbVie have slumped after a pair of failed phase 2 trials for emraclidine, a schizophrenia drug it acquired as part of its $8.7 billion takeover of Cerevel Therapeutics last year.
a Represents net earnings (loss) attributable to AbbVie Inc. Intangible asset impairment reflects a partial after-tax impairment charge of $3.5 billion related to the emraclidine intangible asset ...
Positive Phase 2 data for emraclidine, expected by the end of 2024, could potentially unlock a multi-billion dollar market opportunity. AbbVie has been proactive in strengthening its portfolio and ...
Also Read: AbbVie’s Early Parkinson’s Candidate Hits Primary Goal In Pivotal Late-Stage Study Despite this, the company sees potential in exploring emraclidine as an adjunctive treatment ...
So is the stock worth buying today? AbbVie had a recent setback in November when it announced poor phase 2 study results for emraclidine. The once-promising drug was a potential blockbuster for ...
AbbVie is pushing Skyrizi and Rinvoq to counter ... months after its experimental schizophrenia drug emraclidine failed in two mid-stage studies. "We're still optimistic about the asset," said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results